| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2011091134 |
| Title |
Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Metabolic Disorders. |
| Abstract |
The invention provides methods and compositions for selectively promoting anti- metabolic disorder activity over classical PPAR gamma activation through modulation of PPAR gamma phosphorylation (e.g., Ser-273 phosphorylation of murine peroxisome proliferator activated receptor gamma (PPAR gamma) 2 or a corresponding serine residue in a murine PPAR gamma 2 homolog, including a human). Also provided are methods for preventing, treating, or predictiving responsiveness of therapies for metabolic disorders in a subject through selective inhibition of such PPAR gamma phosphorylation. Further provided are methods for identifying compounds that are capable of modulating such PPAR gamma phosphorylation. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Representative Drug(s) |
D0H5FI |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0PO7F
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2014120538 |
| Title |
Ppar Agonists for Treatment of Multiple Sclerosis. |
| Abstract |
Methods of treatment of multiple sclerosis (MS) with PPARgama agonists, and in particular with the compound of formula (I) known as INT131. |
| Applicant(s) |
Intekrin Therapeutics, Inc |
| Representative Drug(s) |
D0G3KY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012124311 |
| Title |
Novel Phenylpyridine Derivative and Drug Containing Same. |
| Abstract |
The present invention provides: a compound, represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARgama activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazole-5(4H)-one ring; X represents C-R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar. |
| Applicant(s) |
Kowa Company, Ltd |
| Representative Drug(s) |
D0NF8V |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012108677 |
| Title |
Novel Compound Having Skin-Whitening, Anti-Oxidizing and Ppar Activities and Medical Use Therefor. |
| Abstract |
The present invention relates to a novel compound having skin-whitening, anti-oxidizing and PPAR activities and to a medical use therefor. Compounds according to the present invention can be used to advantage in skin-whitening pharmaceutical compositions or cosmetics as they have a skin-whitening activity whereby tyrosinase is inhibited, and can be used to advantage in the prevention or treatment of skin ageing or the like as they have an anti-oxidizing activity, and can also be used as pharmaceutical compositions or health foods which are useful in preventing and treating obesity, metabolic disease or cardiovascular disease as they have PPAR activity and, more particularly, PPAR and PPAR activity. |
| Applicant(s) |
Pusan Nat University Industry University |
| Representative Drug(s) |
D05AUY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012058649 |
| Title |
Cis 3,4-Dihydroxy-2-(3-Methylbutanoyl)-5-(-3-Methylbutyl)-4-(4-Methylpentanoyl)Cyclopent-2-En-1-One Derivatives, Substantially Enantiomerically Pure Compositions and Methods. |
| Abstract |
The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)- 3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (-)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes. |
| Applicant(s) |
Kindex Therapeutics, Llc |
| Patent ID |
WO2012021467 |
| Title |
Synthesis for Thiazolidinedione Compounds. |
| Abstract |
The present invention provides novel methods for synthesizing PPARy sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases. |
| Applicant(s) |
Metabolic Solutions Development Company, Llc Tanis, Steven, P. Parker, Timothy Gadwood, Robert, C. Zeller, James, R. Artman, Gerald, D., Iii Larsen, Scott, D |
| Representative Drug(s) |
D0UH5B |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011117429 |
| Title |
Cannabinoid Quinone Derivatives. |
| Abstract |
Cannabinoid quinone derivatives.The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases. |
| Applicant(s) |
Vivacell Biotechnology Espana Sl |
| Representative Drug(s) |
D0ZO0D |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011098801 |
| Title |
Inflammatory Disease Treatment. |
| Abstract |
Compounds of formula (I) are useful in the treatment of inflammatory disease wherein at least 95% by weight of the said compound of formula (I) is in the stereoconfiguration shown in formula (IA) and less than 5% by weight is in the stereoconfiguration shown in formula (IB) in which formulae (I), (IA) and (IB): R is CH3- or hydrogen; X1 is -OR1, -S(O)nR2 or -NR3R4 and X2 is-OH; or X1 and X2 taken together represent a radical *-OC(O)NH-** or *-C(O)N(H)O-** wherein the bond marked * is attached to the carbon to which W and R are attached, and the bond marked ** is attached to the carbonyl carbon; R1 and R2 are independently C1-6 alkyl optionally substituted with one or more halogen atoms; C1-6 alkoxyalkyl; or aryl R3 and R4 are independently hydrogen; C1-6 alkyl; aryl; a group -C(Ra)=C(Rb)-C(=O)-Ara wherein Ra and Rb are independently hydrogen or C1-6 alkyl and Ara is aryl; or a group -Arb-C(=O)-Arc wherein Arb and Arc are aryl; or -C(=O)O-Rc wherein Rc is an aryl or C1-6alkyl; or R3 and R4 taken together with the nitrogen to which they are attached form a saturated ring of 3 to 7 ring members or an unsaturated ring of 5 to 7 ring members; n is 0,1 or 2; W is a group which when linked to the -C(R)(X1)C(=O)X2 results in a compound (I) having PPARgama agonist activity. |
| Applicant(s) |
Pulmagen Therapeutics (Inflammation) Limited |
| Representative Drug(s) |
D0GG5K |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011077712 |
| Title |
Novel 1-(Biphenyl-4-Yl-Methyl)-1H-Imidazole Derivative and Pharmaceutical Product Containing Same. |
| Abstract |
Disclosed is a novel 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative represented by general formula (I), which has both angiotensin II receptor antagonist activity and PPAR- activating activity and. |
| Applicant(s) |
Kowa Company, Ltd |
| Representative Drug(s) |
D0U6AW |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2010095462 |
| Title |
Novel Compounds Comprising A 3-(5-Alkoxypyrimidin-2-Yl) Pyrimidin-4(3H)-One Structure and Drugs That Comprise Same. |
| Abstract |
Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease. |
| Applicant(s) |
Kowa Company, Ltd |
| Representative Drug(s) |
D0LA6O |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2010076553 |
| Title |
Sulfonamide Compounds for The Treatment of Respiratory Disorders. |
| Abstract |
Compounds of formula (I) are agonists of PPARgama, useful for the treatment of respiratory disease; formula (I): wherein R1, R2 or R3 each independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; R4 represents hydrogen or alkyl; m, n or p independently represents 0, 1, 2 or 3. |
| Applicant(s) |
Pulmagen Therapeutics (Inflammation) Limited |
| Representative Drug(s) |
D0HT9C |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2009026658 |
| Title |
Ppar Agonists. |
| Abstract |
The present invention relates to PPAR agonists and their use in therapy, including the treatment of disease. In particular, the invention relates to compounds which are PPAR-gamma agonists and/or PPAR alpha/gamma dual agonists. |
| Applicant(s) |
The University of Sydney |
| Representative Drug(s) |
D0O5IN |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2009021467 |
| Title |
Method and Network System of Multimedia Broadcast Multicast Service Transmitting. |
| Abstract |
A transmitting method of multimedia broadcast multicast service is disclosed, including: a main-entity receives MBMS data; the service data is processed by the main-entity via radio link control RLC layer and medium access control MAC layer, the data block processed by MAC layer and air interface sending time sign are sent to an accessory equipment of the main-entity; the data block received in the process adds the air interface sending time sign for forming data packet and sends to a sub-entity; the sub-entity sends the air interface sending time sign and the data block processed by MAC layer to an accessory equipment of the sub-entity; at the air interface sending time, the accessory equipment of the sub-entity and the accessory equipment of the main-entity sends the data block processed by MAC layer. Using the solution of this application, synchronous transmitting of MBMS service is realized. |
| Applicant(s) |
Huawei Technologies Co., Ltd |
| Representative Drug(s) |
D0HW6Y |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008141897 |
| Title |
Composition Useful for The Prevention of Adverse Effect Due To The Use of Ppar-Gamma Agonists. |
| Abstract |
The present invention relates to the use of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, for the prevention of theadverse effects,such as steoporosis, weight gain and edema, due to the use ofPPAR-gamma agonists selected from the group consisting of spirolaxine or a glitazonederivative selected fromthe group consisting ofroglitazone, pioglitazone androsiglitazone. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D03GFB |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008137105 |
| Title |
Method of Treatment Using Fused Aromatic Compounds Having Anti-Diabetic Activity. |
| Abstract |
Fused aromatic compounds of Formula I are PPAR gamma agonists or partial agonists and are useful for weekly dosing in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. |
| Applicant(s) |
Merck & Co., Inc |
| Representative Drug(s) |
D0UG1W |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008109334 |
| Title |
Novel Crystalline Salt form of An Antidiabetic Compound. |
| Abstract |
A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for making pharmaceutical formulations for the treatment of type 2 diabetes, hyperglycemia, obesity, and dyslipidemia. |
| Applicant(s) |
Merck & Co., Inc |
| Representative Drug(s) |
D0M4RD |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008108602 |
| Title |
Novel Phenylpropionic Acid Derivatives As Peroxisome Proliferator-Activated Gamma Receptor Modulators. |
| Abstract |
The present invention provides a novel phenylpropionic acid derivative and a PPAR-gama modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-gama and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases. |
| Applicant(s) |
Dong-A Pharm. Co., Ltd |
| Representative Drug(s) |
D09OXG |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008099794 |
| Title |
Fused Ring Compounds As Partial Agonists of Ppar-Gamma. |
| Abstract |
The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The resent invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. |
| Applicant(s) |
Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0SL0K |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008004341 |
| Title |
A-Substituted Phenylpropionic Acid Derivatives. |
| Abstract |
The invention provides alpha-substituted phenylpropionic acid derivatives functioning as ligands of PPAR's alpha, and gama. alpha-Substituted phenylpropionic acid derivatives represented by the general formula shown below; pharmaceutically acceptable salts thereof; or hydrates of both: [Chemical formula] wherein R1 is trifluoromethyl, substituted or unsubstituted phenyl, cycloalkyl of 4 to 8 carbon atoms, substituted or unsubstituted adamantyl, carboranyl, or diamantyl; R2 is hydrogen or halogeno; R3 is alkoxy of 1 to 10 carbon atoms or benzyloxy; R4 is lower alkyl of 1 to 6 carbon atoms; and R5 is hydrogen or halogeno. |
| Applicant(s) |
National University University of Tokyo |
| Representative Drug(s) |
D0E9GF |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014177593 |
| Title |
Amorfrutin Analogs As Ppargamma-Modulators. |
| Abstract |
The present invention relates to Amorfrutin analogues and stereoisomeric forms, solvates, hydrates, conjugates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these Amorfrutin analogues together with pharmaceutically acceptable carrier, excipient and/or diluents. Said Amorfrutin analogues have been identified as modulators of the peroxisome proliferator-activated receptors (PPARs), especially PPAR and are useful for the prevention and treatment of metabolic diseases, inflammatory diseases, cancer and preparation of phytomedicals and/or functional food products for prevention of metabolic diseases. |
| Applicant(s) |
Boyce Thompson Institute for Plant Research Inc |
| Patent ID |
WO2012117013 |
| Title |
Composition Comprising Peroxisome Proliferator-Activated Receptor-Gamma (Ppar). |
| Abstract |
An injectable composition comprising peroxisome proliferator-activated receptor-gamma for subcutaneous administration and a method for improving imperfections of the skin, wherein the injectable composition is subcutaneously administered at the area of skin imperfections comprising the steps: a) identifying an area of skin imperfections, b) administering a safe and cosmetically effective amount of the composition subcutaneously to the area of skin imperfections. |
| Applicant(s) |
Merz Pharma Gmbh & Co Kgaa |
| Patent ID |
WO2011156136 |
| Title |
Use of Eclipta Prostrata and Other Ppar-Gamma Inhibitors In Cosmetics and Compositions Thereof. |
| Abstract |
The present invention describes compositions and methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of excess accumulation and/or production of subcutaneous fat, such as cellulite, and conditions related thereto, by topically applying compositions comprising Eclipta prostrata extracts or other anti-lipid agents. |
| Applicant(s) |
Avon Products, Inc |
| Patent ID |
WO2010105103 |
| Title |
Compositions and Methods for Prophylaxis and Treatment of Addictions. |
| Abstract |
The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviours, including pathological gambling and pathological overeating. |
| Applicant(s) |
Omeros Corp |
| Patent ID |
WO2010028370 |
| Title |
Use of Ppar Gamma Modulators To Treat Cystic Liver Diseases. |
| Abstract |
Compositions comprising compounds that modulate PPARgama activity and methods for using the compositions in treating liver and bile duct disease are described. Compositions and methods for treating polycystic liver disease are also described. |
| Applicant(s) |
Indiana University Research and Technology Corporation |
| Patent ID |
WO2009153373 |
| Title |
Dermatological Pharmaceutical Composition for The Treatment of Skin Inflammation Diseases, Such As Dermatitis, Atopic Dermatitis, Vitiligo, Alopecia Areata, Acne, Psoriasis, Pruritus. |
| Abstract |
The invention relates to a dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis and pruritus. The invention comprises a basic anti-inflammatory agent, such as indometacin; one or more optional active principles selected alternatively from among at least a corticoid and an antibiotic; and a combination of topical antioxidants used to potentiate the anti-inflammatory effect, selected from among green tea, lipoic acid, curcumin, ascorbyl palmitate, Coenzyme Q10, resveratrol, Pycnogenol, L-camosine, taurine, vitamin E, vitamin C, papaya extract, isoflavones, manganese, lycopene and quercetin. At least one of the topical antioxidants is a peroxisome proliferator-activated receptor-gamma (PPAR-gama) activator. The invention also includes at least one antioxidant substance with an antiproliferative effect on keratonocytes, e.g. manganese, and at least one substance that blocks tumour necrosis factor-alpha (TNF-alpha) or other cytokines that provoke the acute phase of the inflammatory reaction, also with an antiproliferative effect, e.g. pentoxifylline. |
| Applicant(s) |
Umbert Millet, Ignacio |
| Patent ID |
WO2009107652 |
| Title |
Agent for Enhancing Corneal Epithelial Barrier Function. |
| Abstract |
The invention relates to a pharmacological action of a compound which functions as a PPARgama agonist on the barrier function of the corneal epithelium. A PPARgama agonist such as rivoglitazone, DRF-2593, GW-544 or BMS-298585 exhibits an excellent effect of enhancing the corneal epithelial barrier function in a test for enhancement of corneal epithelial barrier function, and therefore is useful as a preventive agent or a therapeutic agent for ocular infection or ocular unidentified complaint caused by a decrease in the corneal epithelial barrier function. Further, the PPARgama agonist can enhance the corneal epithelial barrier function of diabetic patients, patients with decreased corneal epithelial barrier function due to aging and patients who underwent refractive surgery such as PRK (photorefractive keratectomy) or LASIK (laser in situ keratomileusis) or cataract surgery. |
| Applicant(s) |
Santen Pharmaceutical Co., Ltd |
| Patent ID |
WO2008063842 |
| Title |
Methods of Treating Neuropathic Pain with Agonists of Ppar-Gamma. |
| Abstract |
Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the use of PPARgamma agonists for the treatment of mammalian pain. |
| Applicant(s) |
Aestus Therapeutics, Inc |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20110160462 |
| Title |
Crystalline forms of Thiazolidinedione Compound and Its Manufacturing Method. |
| Applicant(s) |
Daiichi Sankyo Co., Ltd |
| Representative Drug(s) |
D0TF0T |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20100144884 |
| Title |
Novel 3-Phenyl Acrylic Acid CompoundActivators of Type Ppar Receptors and Pharmaceutical/Cosmetic Compositions Comprised Thereof. |
| Applicant(s) |
Galderma Research & Development |
| Representative Drug(s) |
D0SV6U |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20100022603 |
| Title |
Bicyclic Aryl-Sulfonic Acid [1,3,4]-Thiadiazol-2-Yl-Amides, Processes for Their Preparation, Pharmaceutical Compositions and Methods for Their Use. |
| Applicant(s) |
Sanofi-Aventis |
| Representative Drug(s) |
D0V0JN |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20090012129 |
| Title |
Novel Biaromatic Compounds That Modulate Ppar-Receptors. |
| Applicant(s) |
Galderma Researh & Development |
| Representative Drug(s) |
D0O8PR |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20110034380 |
| Title |
Combination of A Selective Ppar-Gamma Modulator and An Incretin for The Treatment of Diabetes and Obesity. |
| Representative Drug(s) |
D0G3KY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20140024692 |
| Title |
Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of Ppargamma. |
| Applicant(s) |
Aestus Therapeutics, Inc |
| Patent ID |
US20080262047 |
| Title |
Ppar-Gamma Agonists for Improvement of Cognitive Function In Apoe4 Negative Patients. |
| Applicant(s) |
Smithkline Beecham |
| European Patent Office (EPO) |
| Patent ID |
EP20132612553 |
| Title |
Compositions and Methods for Prophylaxis and Treatment of Addictions. |
| Applicant(s) |
Omeros Corp |
| Japan Patent Office (JPO) |
| Patent ID |
JP2012041334 |
| Title |
Novel A-Substituted Propionic Derivatives. |
| Applicant(s) |
Okayama University |
| Representative Drug(s) |
D0M5YQ |
Drug Info
|
N.A. |
[1] |
